ASPIRE has signed a letter to Congressman Schrader and Congressman Kinzinger to support the BIOSIM Act. This act would accelerate patient access to new biosimilar treatments by providing a temporary increase to physician reimbursement. Under Medicare Part B, biosimilars are currently reimbursed at the average sales price (ASP) +6%. The BIOSIM Act would increase biosimilar reimbursement by two percent to ASP+8%. Importantly, the policy only applies when a biosimilar’s price is lower than the price of the brand-name reference biologic. This guarantees savings to Medicare and reduces out-of-pocket costs for seniors. For these reasons, we, the undersigned organizations, are pleased to endorse the BIOSIM Act.

We are proud to support the #BIOSIMAct along with about 2 dozen other healthcare leaders. This important legislation guarantees savings to Medicare and reduces out-of-pocket costs by streamlining #biosimilars into the U.S. marketplace. 

  • 60 Plus Association
  • Advocacy & Awareness for Immune Disorders Association
  • Allergy & Asthma Network
  • Alliance for Aging Research Alliance for Retired Americans
  • Alliance to Solve PANS & Immune-Related Encephalopathies (ASPIRE)
  • American Consumer InstituteBlack Women’s Health Imperative 
  • CancerCare Center for Freedom and Prosperity
  • Consumer ActionDallas-Fort Worth Business Group on Health
  • Endocrine SocietyHealthy
  • Women Hypertrophic Cardiomyopathy Association
  • International Pemphigus and Pemphigoid Foundation
  • Lupus Foundation of America
  • Men’s Health Network National Center & Caucus on Black Aging
  • National Consumers League
  • Patients Rising Now
  • R Street
  • Institute Rheumatology
  • Nurses Society
  • Scleroderma Foundation
  • Sister’s Network, Inc.
  • Sjögren’s Foundation
  • Texas Business Group on Health
  • The Mended Hearts, Inc

Leave a comment